European Financial Services

 

Worldwide COVID-19 grants

NIH: NIAID – Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01, Clinical Trial Not Allowed) – PAR-20-178

Subsidy: no limit

Deadline: Applications will be accepted on a rolling basis, beginning on 30 April 2020.

Consortium: Both US and non-US for profit and non-profit organizations can apply.

Scope: The purpose of this grant is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). Examples of research areas are: studies to understand the viral infection, replication and pathogenesis, studies to understand viral transmission, identification and characterization of immunity, development of clinical diagnostic tests and therapeutics (in vitro, ex vivo or animal models), vaccines, and more.

NIH: NIAID- Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21, Clinical Trial Not Allowed) – PAR-20-177

Subsidy: $275,000 (max. $200,000 in one year)

Deadline: Applications will be accepted on a rolling basis, beginning on 30 April 2020

Consortium: Both US and non-US for profit and non-profit organizations can apply.

Scope: The purpose of this grant is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). Examples of research areas are: studies to understand the viral infection, replication and pathogenesis, studies to understand viral transmission, identification and characterization of immunity, development of clinical diagnostic tests and therapeutics (in vitro, ex vivo or animal models), vaccines and more.

 

Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

Subsidy: no limit

Deadline: Stage 1: 30 April 2020, 31 July 2020, 31 October 2020. Full proposal on invitation only.

Consortium: All researchers from anywhere in the world. Both for-profit and non-profit organizations are eligible.

Scope: projects must fall under one of the areas of interest.

  • Area of interest #7: emerging diseases diagnostics: diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)

  • Area of interest #8: Influenza and emerging infectious diseases vaccines: COVID-19 vaccine

  • Are of interest #9: influenza and emerging infectious diseases therapeutics: COVID-19 therapeutics

  • Area of interest #17: (NEW) Advanced Manufacturing technologies: The development and demonstration of innovations and enhancements to manufacturing platforms to support the development of necessary medical countermeasures including vaccines and therapeutics in prevention, preparation, and response to COVID-19.

NIH: NIAID- Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21, Clinical Trial Not Allowed) – PAR-20-177

Subsidy: $275,000 (max. $200,000 in one year)

Deadline: Applications will be accepted on a rolling basis, beginning on 30 April 2020

Project duration: 2 years

Consortium:  Both US and non-US for profit and non-profit organizations can apply.

Scope: The purpose of this grant is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). Examples of research areas are: studies to understand the viral infection, replication and pathogenesis, studies to understand viral transmission, identification and characterization of immunity, development of clinical diagnostic tests and therapeutics (in vitro, ex vivo or animal models), vaccines and more.

NIH: Rapid Acceleration of Diagnostics (RADx) initiative

Subsidy: no limit (total budget $500M)

Deadline: a rolling basis and will be reviewed within a week of receipt. Progression to ‘ deep dive stage’ upon invitation.

Project duration: depends on development stage, support incl. commercialization and product distribution

Consortium: US scientists and inventors

Scope: To address the COVID-19 pandemic, this program is anticipated to support the fast track development of new tests with improved technical performance and convenience, such as point-of-care and home devices, as well as innovations that make current lab tests faster, more efficient, and more widely accessible. Focus is on improving analytical or operational performance, improving access and reducing cost of testing.  NIBIB will consider innovations at all stages of readiness from early to late stage and from novel testing strategies to optimization of existing SARS-CoV-2 testing approaches. NIBIB will support the full range of product development including commercialization and product distribution. NIH will supply the needed budget, partnerships and other resources to fully deploy successful tests to the public on the shortest possible timeline.  NIH will negotiate cost sharing with for-profit institutions as appropriate.

European COVID-19 grants

Vinnova- Innovation projects in the health field that dampen the prevalence and effects of the covid-19 pandemic

Subsidy: up to 5M SEK, co-financing is required

Deadline: 18 August 2020

Consortium: consortium must consist of at least 2 partners. One from business or health care and other from the following sectors: health care, public sector, academia, business and civil society.

Scope: Health-related innovation projects and feasibility studies are funded within the call for proposal. These should help to curb the spread and effects of the covid-19 pandemic and prevent future pandemics. The results of the innovation projects should be implemented and utilized already during the ongoing pandemic, and the results of the feasibility studies will lead to increased preparedness for future pandemics.

Vinnova- Pre-studies for innovation projects in the health area that prevent future pandemics

Subsidy: up to 1M SEK, co-financing is required

Deadline: 18 August 2020

Consortium: consortium must consist of at least 2 partners. One from business or health care and other from the following sectors: health care, public sector, academia, business and civil society.

Scope: Pre-health studies to strengthen preparedness for future pandemics.

MedTech OITBs join forces in the fight against COVID-19

Subsidy: TBD

Deadline: Expressions of interest will be accepted starting 15 September 2020

Consortium: (TBD); pan-European SMEs

Scope: Innovative SMEs working on the development of solutions to fight the virus will be able to apply to this call. The three MedTech Open Innovation Testbed (OITBs): TBMED, MDOT and SAFE-N-MEDTEC thus initiate a call for expressions of interest from MedTech SMEs performing COVID-19-related developments. Support will be provided in the following ways:

  • TBMED offers services to SMEs from the high-risk medical devices sector, particularly with regard to characterization, prevention, diagnosis, treatment, follow-up and the forecast of patient prognosis related to COVID-19. Such services include, among others, early dialogues with the Basque HTA office, expert advice for regional and/or multinational clinical trials on COVID-19 and the assessment of needs of such companies regarding clinical trials

  • MDOT members who develop routines and processes to accelerate the conformity assessment of medical devices, offer consultation regarding regulatory affairs and technology development in the fields of inhalation technologies and environmental sensors.

  • SAFE-N-MEDTECH with its key expertise in nano-enabled medical technologies, offers characterization, preclinical validation, access to biobanks and patient samples, scale up and regulatory support, technology assessment and horizon scanning.

MERCK KGaA: Research Grant for pandemic preparedness 

Subsidy: up to  €500,000/year

Deadline: on a daily basis

Project duration: 3 years with the option of extension

Consortium: Globally, scientists in all career stages who are affiliated with any research-based institution, university or company.

Scope: The recent COVID-19 pandemic shows that pandemic preparedness and having the right products and technology to fight infectious diseases with epidemic and pandemic potential is of utmost importance. 

Proposals will be considered that leverage technological solutions to be more prepared for pandemic outbreaks or solutions that could help to fight emerging viral infections.

Pre-outbreak R&D Preparedness for pandemic disease:

  1. Assessing the priority of pathogens and diseases with epidemic threat

  2. Platform technologies to accelerate the development of vaccines, drugs, diagnostics, vector control tools and delivery systems needed to control emerging health threats

  3. Innovative technologies for better personal protection equipment for infection control

 

Response during outbreak:

  1. Novel health technologies (e.g. AI, bioelectronics, diagnostics) for early screening of potential infected patients and treatment facilitation.

  2. Fast-track identifying, testing and production of effective drugs and vaccines during outbreak

AMable: Call for Solution Ideas (COVID-19)

Total budget: €350,000

Deadline: 1 October 2020

Project duration: 6-12 weeks

Consortium: An entity that applies for financial support needs to be a natural person or a legally recognised company of any type, registered within the European Union or a country that is linked to the H2020 program. Preference will be given to SMEs and midcaps. Research and technology development organisations are not eligible, nor consortium members.

Scope: Support activities that propose a realistic solution to a practical challenge. Challenges that society currently sees in coping with the COVID-19 pandemic.  The AMable consortium will publish these challenges in so called “challenge sets” on its web site. These challenges will be regularly updated. When talking about challenges from such a challenge set, we mean e.g. a lack of equipment, helpful tools, replacement parts or parts that enable additional functionality. Overall, such challenges need to be solved when additive manufacturing provides a solution. 

The applicants need to provide the following to be selected for support:

  • A solution idea that would solve the selected challenge by additive manufacturing. The proposal needs to sketch the baseline of that idea. 

  • A list of tasks that need to be addressed to create the solution and the support that the proposer expects from the AMable consortium. 

  • List of the proposer’s expected effort to develop a first prototype of the solution, budget for personnel cost and consumables. (do not address cost of the support from AMable experts here)

German COVID-19 grants

Deutsche Forschungsgemeinschaft (DFG)- Call for Multidisciplinary research into Epidemics and Pandemics in Response to the Outbreak of SARS-CoV-2

Deadline:  Letter of intent: 1 July 2020. Full proposal: 1 September 2020

Consortium: Researchers (single applicant or consortium) based at universities, universities of applied sciences, non-university research institutions and healthcare facilities. Applicants should aim to cooperate with international researchers.

Scope: Funding is available for multi-disciplinary projects addressing the prevention, early detection, containment and investigation of the causes, impacts and management of epidemics and pandemics, taking the example of SARS-CoV-2 and other microorganisms and viruses that are pathogenic to humans. This includes for example, the investigation of:

  • The challenges and effects of an epidemic or pandemic and of measures taken for healthcare systems;

  • Psychological, social and cultural factors in the emergence, spread and treatment of epidemics and pandemics and the legal and ethical implications;

  • The impacts on global and regional economic development, production and value creation chains, logistics, transport and communication;

  • Fundamental biological and medical aspects of a pathogen and the associated symptoms, as well as therapeutic methods or preventive measures in combination with one or more of the above topic areas.

Nordic COVID-19 grants

(Sweden) FORMAS: Urgent grants 2020 to secure access to data or research materials

Subsidy: Costs corresponding to the urgent need.

Deadline:  31 August 2020

Consortium: Participating researchers must have obtained their doctoral degree. Grants for research projects may only be administered by a Swedish university, college or other Swedish public organisation that meets Formas’ criteria for administrating organisations.

Scope: In view of Covid-19 and the current situation in Sweden and the world, Formas’ Research Council has decided to open its urgent call immediately. Formas wants to provide the opportunity to collect data and research materials of an urgent nature to ensure the future availability of research.

Applications are welcome within all Formas’ areas of responsibility that demonstrate an urgent need to secure future access to data (measurement data, collection of samples, etc.) or other research materials (interviews, participating observations, etc.). Applications from all scientific disciplines are welcome: the humanities, natural sciences, social sciences and technology, as well as for interdisciplinary approaches.

Other COVID-19 grants

France: ANR Recherche-Action Covid-19

Subsidy: max. €150,000

Deadline:  28 October 2020

Consortium: Main applicant: a full-time researcher who is a member of a French organization or research institution or of a company with headquarters located in France.

Scope: This call aims to complement the initial action of Flash COVID-19 and addresses the following five priorities:

  1. Epidemiological studies (i.e. New methods of diagnosing infection and asymptomatic carriage and studies of seroprevalence)

  2. Physiopathogenesis of the disease (i.e. new therapeutics; development of animal and cellular models of the disease; evolution of the immune response, nature and duration of acquired immunity)

  3. Infection prevention and control (i.e. mode of virus transmission and study of human and environmental factors influencing)

  4. Ethics and social dynamics (i.e. research and care ethics and human rights; Communication and crisis management)

  5. Global issues of the Covid-19 epidemic (i.e. understanding of the ecological, environmental and human factors at the origin of the emergence of the pandemic and identification of practices to limit the risks future (including international agreements); macro and micro-economic impact and on trade flows of goods and services (including financial)

France DIM Elict: special call for proposals development of innovative technologies & methods to fight SARS-COV-2

Subsidy: €15,000 of running costs and/or human resources and/or €30,000 of equipment

Deadline:  open until the further notice (the end of the crisis)

Consortium: Any research team (laboratories, likely non-profit organizations) from the Ile de France region (The region is made up of eight administrative departments: Paris, Essonne, Hauts-de-Seine, Seine-Saint-Denis, Seine-et-Marne, Val-de-Marne, Val-d’Oise and Yvelines) can apply with a project linked to the infectious agent SARS-CoV-2

Scope: The DIM ELICIT would like to support projects developing innovative technologies and methods regarding the analysis, diagnosis and/or treatment to fight SARS-CoV-2.

The technologies targeted in this call will have to belong to at least one Core technologies and one End-user applications:

Core technologies

  • Microfludics

  • Biophotonic and waves

  • Image analysis and Big Data

End-user applications

  • Single Cell/Single molecule

  • Organ on chips

  • Technologies for in vivo biology

  • High Tech – Low Cost technologies

Note: Projects will have to be written in English. The projects submitted must target the acquisition of knowledge.

UK Research and Innovation (UKRI) – Get funding for ideas that address COVID-19

Subsidy: No limit

Deadline:  Open (apply at any time)

Consortium: UK based business at any stage or size. Researchers holding existing UKRI standard grants can apply to switch their funding to address the objectives of this call.

Scope: Proposals are invited for short-term projects addressing and mitigating the health, social, economic, cultural and environmental impacts of the COVID-19 outbreak.

UKRI will support excellent proposals which meet at least one of the following:

  • New research or innovation with a clear impact pathway that has the potential (within the period of the grant) to deliver a significant contribution to the understanding of, and response to, the COVID-19 pandemic and its impacts.

  • Supports the manufacture and/or wide scale adoption of an intervention with significant potential

  • Gathers critical data and resources quickly for future research use

UKRI: COVID-19 Rapid Response Rolling Call

Subsidy: no max

Deadline:  1 April 2021

Consortium: Academic Principal Investigators hosted by a UK institution (eligible for UKRI funding) or SMEs, government arm’s length bodies, and NHS organisations, and equivalent UK authorities are also encouraged to apply.

Scope: The research scope of this call is as below:

  • Virology, Immunity and Pathophysiology;

  • Diagnostics;

  • Epidemiology (Transmission, Disease Susceptibility and Severity, Control and Mitigation);

  • IPC and PPE;

  • Public Health, Media and Communication (Public Health; Media and communication);

  • Clinical Management;

  • Primary, Adjunctive and Supportive Therapies;

  • Vaccines;

  • Health and Care Delivery;

  • Underpinning

CONTACT US

Rue Saint-Laurent 2/101,1000 Brussels, Belgium

European Financial Services

Rue Saint-Laurent 2/101,1000 Brussels, Belgium

info@eufis.be

  • Facebook
  • LinkedIn

©2020 by European Financial Services